A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis (COAST-W)
I1F-MC-RHBW - ClinicalTrials.gov - NCT02696798
The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in participants with radiographic axial spondyloarthritis (rad-axSpA) who have taken tumor necrosis factor (TNF) inhibitor.
Trial Summary
Age Range
≥18 yearsConditions the trial is for
SpondyloarthritisWhat the trial is testing?
IxekizumabCould I receive a Placebo?
YesEnrollment Goal
316Trial Dates
Apr 12, 2016 - May 3, 2019How long will I be in the trial?
Your participation could last up to 1.5 years and include 15 visits to the study center. After this study, you may be eligible to enter another study that could last up to 2 more years.Trial Phase
IIILilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo